Selumetinib granted US breakthrough therapy designation in neurofibromatosis type 1

AstraZeneca

1 April 2019 - Selumetinib is a MEK 1/2 inhibitor being co-developed by AstraZeneca and MSD.

AstraZeneca and MSD today announced that the US FDA has granted breakthrough therapy designation for the MEK 1/2 inhibitor and potential new medicine selumetinib.

The designation is based on Phase II data from the SPRINT trial, testing selumetinib as an oral monotherapy in paediatric patients, aged three years or older with inoperable NF1-related plexiform neurofibromas.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder